Phase Two Clinical Trials to treat NTM

http://www.nasdaq.com/press-release/ait-therapeutics-announces-enrollment-of-first-patient-into-its-nontm-abscessus-phase-2-trial-in-20170807-00641

AIT Therapeutics Announces Enrollment of First Patient into Its NO-NTM abscessus Phase 2 Trial in Nontuberculous Mycobacteria (NTM)

10 patients with Mycobacterium Abscessus Complex (MABSC) are expected to enroll in the trial Continue reading Phase Two Clinical Trials to treat NTM

Stem cell therapy for lung fibrosis conditions

https://www.sciencedaily.com/releases/2017/08/170803091928.htm

In the journal Respiratory Research, the scientists demonstrated that they could harvest lung stem cells from people using a relatively non-invasive, doctor’s-office technique. They were then able to multiply the harvested lung Continue reading Stem cell therapy for lung fibrosis conditions

Setting the Record Straight About Coughing Up Blood

https://www.cff.org/CF-Community-Blog/Posts/2017/Setting-the-Record-Straight-About-Coughing-Up-Blood/

Hemoptysis, or coughing up blood, is one of the scariest complications of cystic fibrosis, although it doesn’t have to be. “Hemoptysis” is also the name of a heavy metal band, and that is truly scary! Hemoptysis, the medical Continue reading Setting the Record Straight About Coughing Up Blood

New Drug Application Submitted for Treatment of P. aeruginosa

https://bronchiectasisnewstoday.com/2017/07/28/non-cystic-fibrosis-bronchiectasis-candidate-therpay-nda-submitted-for-linhaliq-for-p-aeruginosa-infection/

New Drug Application Submitted for Linhaliq as Treatment of Pseudomonas Aeruginosa Infection in NCFBE Patients

The pharmaceutical company Aradigm has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq Continue reading New Drug Application Submitted for Treatment of P. aeruginosa

Animal model with CF shows promise against infection

http://finance.yahoo.com/news/aeol-20415-protects-lungs-against-130000156.html

AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis

• TREATMENT WITH AEOL 20415 REDUCED INFECTION, IMPROVED BODY WEIGHT AND REDUCED PRESENCE OF WHITE Continue reading Animal model with CF shows promise against infection

Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin

http://finance.yahoo.com/news/raptor-announces-qualified-infectious-disease-113000057.html

Raptor Pharmaceutical Corp. (RPTP) today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to MP-376, the Continue reading Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin

Polyphor awarded $3 million to advance POL6014 in CF

Polyphor and the Cystic Fibrosis Foundation Therapeutics (CFFT) are to advance the clinical development of the inhaled elastase inhibitor POL6014 in cystic fibrosis (CF).

POL6014 reduces the activity of elastase, an enzyme that destroys lung Continue reading Polyphor awarded $3 million to advance POL6014 in CF

Bacteria Strain PAHM4 Differs in Bronchiectasis, CF Patient Lungs

In a recent study entitled “Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains,” researchers investigated the mechanisms the bacteria Continue reading Bacteria Strain PAHM4 Differs in Bronchiectasis, CF Patient Lungs